CoChat

Enduring neurological sequelae of benzodiazepine use: an Internet survey

Open access
Huff, Christy, Finlayson, A. J. Reid, Foster, D. E., Martin, Peter R. · 2023 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Introduction: Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated. Objective: This secondary analysis of the results from an Internet survey sought to better understand the acute and protracted withdrawal symptoms associated with benzodiazepine use and discontinuation. Methods: An online survey ( n = 1207) was used to gather information about benzodiazepine use, including withdrawal syndrome and protracted symptoms. Results: The mean number of withdrawal symptoms reported by a respondent in this survey was 15 out of 23 symptoms. Six percent of respondents reported having all 23 listed symptoms. A cluster of least-frequently reported symptoms (whole-body trembling, hallucinations, seizures) were also the symptoms most frequently reported as lasting only days or weeks, that is, short-duration symptoms. Symptoms of nervousness/anxiety/fear, sleep disturbances, low energy, and difficulty focusing/distractedness were experienced by the majority of respondents (⩾85%) and, along with memory loss, were the symptoms of longest duration. Prolonged symptoms of anxiety and insomnia occurred in many who have discontinued benzodiazepines, including over 50% who were not originally prescribed benzodiazepines for that indication. It remains unclear if these symptoms might be caused by neuroadaptive and/or neurotoxic changes induced by benzodiazepine exposure. In this way, benzodiazepine withdrawal may have acute and long-term symptoms attributable to different underlying mechanisms, which is the case with alcohol withdrawal. Conclusions: These findings tentatively support the notion that symptoms which are acute but transient during benzodiazepine tapering and discontinuation may be distinct in their nature and duration from the enduring symptoms experienced by many benzodiazepine users.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/20451253221145561

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Most respondents who had discontinued benzodiazepines (n=763) reported multiple symptoms from the 23 symptom choices on the survey, and they were typically of long duration. The four symptoms in red were reported by over 85% of respondents. The least frequently reported symptoms appear below in green; of the respondents who experienced these symptoms > 40% found them to be of short duration (days, weeks).
Figure 1. Most respondents who had discontinued benzodiazepines (n=763) reported multiple symptoms from the 23 symptom choices on the survey, and they were typically of long duration. The four symptoms in red were reported by over 85% of respondents. The least frequently reported symptoms appear below in green; of the respondents who experienced these symptoms > 40% found them to be of short duration (days, weeks).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 6

  1. Janhsen K, 2015, Dtsch Arztebl Int, 112, 1
  2. Saitz R., 1998, Alcohol Health Res World, 22, 5
  3. Sachdeva A, 2015, J Clin Diagn Res, 9
  4. Martin PR, 2003, Alcohol Res Health, 27, 134
  5. 10.1111/j.1530-0277.2002.tb02681.x · doi:10.1111/j.1530-0277.2002.tb02681.x · Paper page
  6. Tyrer P., 1993, Biochem Soc Symp, 59, 107

Cited by

See all 21

Metadata

Authors
Huff, C., Finlayson, A. J. R., Foster, D. E., & Martin, P. R.
Affiliations
  • Benzodiazepine Information Coalition, 1042 Ft. Union Blvd., PMB 1030, Midvale, UT, 84047 USA
  • Vanderbilt University Medical Center (US)
  • Benzodiazepine Action Work Group, Colorado Consortium for Prescription Drug Abuse Prevention, Aurora, CO, USA
Corresponding author
Huff, Christy
Venue
Therapeutic Advances in Psychopharmacology
Published
2023-01
Volume
13
Pages
20451253221145561-20451253221145561
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4319316145
Cited by
18
References
38
Citations by year
2026: 2 · 2025: 6 · 2024: 8 · 2023: 2
FWCI
3.58
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
benzodiazepine withdrawal, benzodiazepine tapering, benzodiazepine discontinuation, anxiety, insomnia, memory loss, neural adaptation, neurotoxicity, hallucinations, seizures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enduring neurological sequelae of benzodiazepine use: an Internet survey. https://app.cochat.ai/papers/10.1177/20451253221145561
The paper
Huff, C., Finlayson, A. J. R., Foster, D. E., & Martin, P. R. (2023). Enduring neurological sequelae of benzodiazepine use: an Internet survey. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253221145561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.